Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IPIX | US
0
0%
Healthcare
Biotechnology
30/09/2023
20/03/2026
0.00
0.00
0.00
0.00
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
875.2%1 month
1192.6%3 months
1431.1%6 months
2619.8%-
-
0.45
0.20
0.04
-1.08
202.69
-
-1.99M
414.68K
414.68K
-
-
-
-
-114.34
-
-
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.02
Range1M
0.02
Range3M
0.02
Rel. volume
0.02
Price X volume
1.76
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Biodexa Pharmaceticals | BDRX | Biotechnology | 0.7006 | 406.94K | 2.25% | n/a | 0.00% |
| Syros Pharmaceuticals Inc | SYRS | Biotechnology | 0.0002 | 5.36K | 0.00% | n/a | -954.99% |
| XOMAP | XOMAP | Biotechnology | 25.6 | 0 | -0.58% | 26.27 | 121.93% |
| XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock | XOMAO | Biotechnology | 25.33 | 0 | -0.04% | 25.57 | 121.93% |
| Revolution Medicines Inc. Warrant | RVMDW | Biotechnology | 1.6 | 0 | -15.34% | n/a | 5.40% |
| Rocket Pharmaceuticals Inc. Warrant | RCKTW | Biotechnology | 0.0158 | 0 | -21.00% | n/a | 0.00% |
| ICUCW | ICUCW | Biotechnology | 0.0261 | 0 | n/a | -45.50% | |
| Humacyte Inc | HUMAW | Biotechnology | 0.0887 | 0 | -7.31% | n/a | -63.37% |
| EyeGate Pharmaceuticals Inc | EYEG | Biotechnology | 34.9646 | 0 | -0.98% | n/a | |
| COEPW | COEPW | Biotechnology | 0.0121 | 0 | 22.22% | n/a | 25.11% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
No data | |||||||
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.08 | - | Cheaper |
| Ent. to Revenue | 202.69 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.45 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 1,431.07 | - | Riskier |
| Debt to Equity | 0.20 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 414.68K | - | Emerging |